Avoro Capital Advisors LLC — UNITED THERAPEUTICS CORP UTHR: Quarterly 13F Position History
Avoro Capital Advisors LLC has reported UNITED THERAPEUTICS CORP (UTHR) on 22 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2020. As of Q1 2026, the position is sized at 2,630,000 shares ($1.56B market value, 15.36% of the equity book). Quarter-over-quarter share count change: + 23,940 (+0.9%) .
- 2,630,000Shares Held (Latest Filing)
- $1.56BReported Market Value (Latest Filing)
- 15.36%Portfolio Weight (% of 13F Equity Book)
- +23,940Quarter-over-Quarter Share Change
- +$289.7MQuarter-over-Quarter Value Change
- 3,035,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,630,000 | +23,940 | +0.9% | $1.56B | 15.36% | $592.98 |
| Q4 2025 | 2,606,060 | +583,838 | +28.9% | $1.27B | 12.48% | $487.25 |
| Q3 2025 | 2,022,222 | 347,778 | -14.7% | $847.7M | 10.97% | $419.21 |
| Q2 2025 | 2,370,000 | 305,000 | -11.4% | $681.0M | 11.93% | $287.35 |
| Q1 2025 | 2,675,000 | 85,300 | -3.1% | $824.6M | 12.87% | $308.27 |
| Q4 2024 | 2,760,300 | 98,588 | -3.4% | $973.9M | 13.78% | $352.84 |
| Q3 2024 | 2,858,888 | 0 | — | $1.02B | 14.94% | $358.35 |
| Q2 2024 | 2,858,888 | 0 | — | $910.7M | 12.13% | $318.55 |
| Q1 2024 | 2,858,888 | 0 | — | $656.7M | 7.66% | $229.72 |
| Q4 2023 | 2,858,888 | +6,388 | +0.2% | $628.6M | 8.68% | $219.89 |
| Q3 2023 | 2,852,500 | 57,499 | -2.0% | $644.3M | 10.05% | $225.87 |
| Q2 2023 | 2,909,999 | +39,999 | +1.4% | $642.4M | 8.71% | $220.75 |
| Q1 2023 | 2,870,000 | +5,000 | +0.2% | $642.8M | 9.54% | $223.96 |
| Q4 2022 | 2,865,000 | 61,500 | -2.1% | $796.7M | 11.91% | $278.09 |
| Q3 2022 | 2,926,500 | 43,500 | -1.5% | $612.8M | 11.32% | $209.38 |
| Q2 2022 | 2,970,000 | 60,000 | -2.0% | $699.9M | 13.83% | $235.64 |
| Q1 2022 | 3,030,000 | 5,000 | -0.2% | $543.6M | 9.92% | $179.41 |
| Q4 2021 | 3,035,000 | +35,000 | +1.2% | $655.8M | 11.17% | $216.08 |
| Q3 2021 | 3,000,000 | 0 | — | $553.7M | 8.71% | $184.58 |
| Q2 2021 | 3,000,000 | 0 | — | $538.2M | 9.37% | $179.41 |
| Q1 2021 | 3,000,000 | +150,000 | +5.3% | $501.8M | 8.67% | $167.27 |
| Q4 2020 | 2,850,000 | — | — | $432.6M | 7.45% | $151.79 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a UTHR position in 13F-HR filings?
Avoro Capital Advisors LLC first reported UNITED THERAPEUTICS CORP (UTHR) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in UTHR?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC added 23,940 shares of UTHR (+0.9%), bringing the total reported position to 2,630,000 shares at a market value of $1.56B.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in UTHR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.